StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
9
Publishing Date
2022 - 01 - 10
1
2021 - 09 - 29
1
2021 - 05 - 05
1
2021 - 04 - 09
1
2021 - 03 - 29
2
2021 - 01 - 29
1
2021 - 01 - 25
1
2020 - 12 - 17
1
Sector
Health technology
9
Tags
Acquisition
1
Alliances
3
Application
1
Approval
1
Authorized
6
Biomarkers
1
Biotech-bay
13
Biotechnology
2
Car-t
4
Cell
1
Ceo
1
Ces
1
Chmp
1
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
7
Collaboration
2
Conference
14
Contract
2
Covid
18
Covid-19
11
Deadline
2
Disease
2
Emergency use authorization
2
Enroll
3
Europe
3
Events
16
Fda
3
Financial
2
Financial results
2
Glioblastoma
2
J.p. morgan healthcare conference
2
Lenzilumab
35
Leukemia
3
Merge
3
N/a
10
People
7
Pharm-country
4
Pharmaceutical
11
Phase 1
5
Phase 1b
2
Phase 2
6
Phase 2/3
2
Phase 2b
2
Phase 3
9
Positive
4
Potential
6
Presentation
18
Product-news
2
Publication
2
Regulatory
3
Research
5
Response
2
Results
10
Study
3
Submission
3
Therapeutics
3
Therapy
2
Topline
3
Treatment
9
Trial
4
Entities
Emergent biosolutions, inc.
1
Humanigen, inc.
9
Symbols
ABBV
30
ACHV
6
ADIL
11
ALBO
6
ALDX
11
ALNY
23
AMGN
7
APLS
10
ARQT
11
AVDL
7
AZN
7
BBI
12
BGNE
8
BHC
6
BHVN
8
BIIB
12
BMRN
8
BMY
12
BYSI
10
CHRS
13
CRNX
8
CTXR
9
CYTH
6
DVAX
11
EIGR
9
EXEL
10
GILD
9
HGEN
9
IDYA
8
IMAB
9
INCY
23
INO
8
IONS
9
JAZZ
7
JNJ
29
LLY
47
MDGL
8
MESO
9
MRK
18
MRNA
10
MYOV
11
NOVN
10
NVAX
13
NVCR
8
OCUP
8
ONTX
7
ORMP
7
PFE
21
REGN
26
SAVA
9
SCYX
12
SNY
44
SNYNF
26
SRNE
8
TAK
19
TEVJF
15
TGTX
18
TNXP
10
VERU
10
ZEAL
7
Exchanges
Nasdaq
9
Nyse
1
Crawled Date
2022 - 01 - 10
1
2021 - 09 - 29
1
2021 - 05 - 05
1
2021 - 04 - 09
1
2021 - 03 - 29
2
2021 - 01 - 29
1
2021 - 01 - 25
1
2020 - 12 - 17
1
Crawled Time
12:00
2
13:00
3
14:00
2
17:00
1
18:00
1
Source
www.biospace.com
9
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 3
symbols :
Hgen
save search
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
Published:
2022-01-10
(Crawled : 12:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-98.85%
|
O:
1.75%
H:
0.0%
C:
-1.4%
phase 3
fda
potential
Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
Published:
2021-09-29
(Crawled : 13:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.41%
|
O:
0.33%
H:
5.54%
C:
-0.81%
presentation
results
lenzilumab
phase 3
Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients
Published:
2021-05-05
(Crawled : 17:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.8%
|
O:
-1.0%
H:
12.15%
C:
6.49%
covid
results
lenzilumab
phase 3
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published:
2021-04-09
(Crawled : 12:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.79%
|
O:
0.53%
H:
2.41%
C:
1.41%
positive results
phase 1
positive
results
phase 3
phase 2
glioblastoma
Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19
Published:
2021-03-29
(Crawled : 14:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.74%
|
O:
57.11%
H:
32.85%
C:
-1.68%
covid
results
topline
lenzilumab
phase 3
conference
Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Published:
2021-03-29
(Crawled : 13:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.74%
|
O:
57.11%
H:
32.85%
C:
-1.68%
covid
positive
results
topline
phase 3
lenzilumab
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
Published:
2021-01-29
(Crawled : 13:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.8%
|
O:
2.46%
H:
3.73%
C:
-4.32%
covid
phase 3
lenzilumab
enroll
covid-19
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Published:
2021-01-25
(Crawled : 18:00)
- biospace.com/
EBS
|
$2.04
9.68%
0.49%
930K
|
Health Technology
|
-98.1%
|
O:
0.0%
H:
0.0%
C:
-0.7%
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.82%
|
O:
0.71%
H:
1.32%
C:
-2.74%
covid
contract
phase 3
merge
lenzilumab
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published:
2020-12-17
(Crawled : 14:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.68%
|
O:
-0.26%
H:
26.97%
C:
24.14%
phase 3
phase 1
phase 2
enroll
glioblastoma
Gainers vs Losers
67%
33%
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.